We selected patients in whom the first bone marrow sample had been obtained before any systemic therapy, because therapy might differentially affect different T-cell subsets.
The expression of the mRNAs of these major RAS components of human bone marrow samples has also been quantified by reverse transcription-polymerase chain reaction (RT-PCR) to confirm the presence of the local bone marrow RAS [ 6].
Retrospective analysis of the presence of EZH2 mutations in archived MPN bone marrow samples has not been shown to have prognostic significance in PMF patients (Abdel-Wahab et al. 2010b).
Both peripheral blood and bone marrow samples had been processed for mononuclear cell isolation in room temperature within 2 4 h after sampling.
Bone marrow samples had generally a higher S-phase fraction than blood samples, which is in correspondence with previous findings of Dow et al (1982).
Using NCCLS bone marrow samples, we have screened for FLT3 mutations in the largest sample of pediatric leukemias yet reported.
The blood and bone marrow samples that had been treated in culture with fludarabine (∼10 cells) were initially incubated for 15 min with anti-CD19 PerCP and anti-CD5 APC-conjugated monoclonal antibody (MoAb) (DAKO, Denmark) at room temperature.
For this purpose, the osteogenic potential of the complete BMC population (called MSC postamplification) was compared with bone marrow samples that have been depleted from all CD34+ and CD133+ cells (called depleted MSCs).
The blood and bone marrow samples that had been treated in culture with resveratrol, fludarabine, cladribine, or a mixture of these drugs (∼10 cells) were initially incubated for 15 min with anti-CD19 PE-Cy5 and anti-CD5 APC-conjugated monoclonal antibodies (mAb) (DAKO, Glostrup, Denmark) at room temperature.
"You'd love to know, if you had taken a bone marrow sample a year before, what would you have seen?" Tests of 187 other patients with acute myelogenous leukemia found that none had the eight new mutations found in the first patient.
